Completed PHASE2 INTERVENTIONAL 2-arm NCT00753103

Anti-Cytokine Therapy for Vasculitis (ACTIVE)

Phase II Pilot Cohort Study to Investigate the Safety and Efficacy of Infliximab as Additional Therapy in the Treatment if Anti-Neutrophil Cytoplasm Antibody Associated Vasculitis

Sponsor: University Hospital Birmingham NHS Foundation Trust

Conditions Microscopic Polyangiitis Renal Limited Vasculitis Wegener's Granulomatosis

Interventions Azathioprine Cyclophosphamide Infliximab Methylprednisolone Mycophenolate mofetil Plasma exchange Prednisolone

Updated 4 times since 2017 Last updated: Sep 15, 2008 Started: Jan 31, 2003 Primary completion: Jul 31, 2006 Completion: Jul 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Microscopic Polyangiitis and Renal Limited Vasculitis, this trial is completed. The trial is conducted by University Hospital Birmingham NHS Foundation Trust and has accumulated 4 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2017 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital Birmingham NHS Foundation Trust

Data source: University Hospital Birmingham NHS Foundation Trust

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Birmingham, United Kingdom